Allen Institute for Artificial Intelligence
supp.ai logo
supp.ai

Discover Supplement-Drug Interactions

Disclaimer: The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The tool is not a substitute for the care provided… (more)
Last Updated: 2 months ago

Possible Interaction: Progesterone and Trilostane

supplement:

Progesterone

Research Papers that Mention the Interaction

Progesterone and estradiol production was significantly reduced in the women receiving trilostane , with maintenance of diurnal cortisol variation.
Trilostane is a 3beta-hydroxysteroid dehydrogenase inhibitor which reduces progesterone production.
Human reproduction  •  2002  |  View Paper
Inhibition of endogenous progesterone production with trilostane or knockdown of PRA expression with small interfering RNA significantly enhanced the glucocorticoid receptor (GR)-mediated COX-2 induction by cortisol, whereas overexpression of PRA attenuated the induction by cortisol.
The Journal of clinical endocrinology and metabolism  •  2009  |  View Paper
Inhibition of endogenous progesterone production with trilostane enhanced 11beta-HSD2 activity.
Biology of reproduction  •  1998  |  View Paper
In study 2, trilostane treatment decreased (P < 0.05) progesterone concentrations by 91% on day 1 of culture but had no effect on VEGF concentrations on any day.
Human reproduction  •  1997  |  View Paper
Trilostane afforded reduction of plasma levels of aldosterone, progesterone , deoxycorticosterone, 17-OH progesterone, cortisol, delta 4-androstenedione, and urinary excretion of 17-hydroxycorticosteroid.
Urology  •  1985  |  View Paper
Trilostane (0.1-1 muM) completely blocked conversion of pregnenolone to progesterone and OH-progesterone; the release of androstenedione was at most only halved, whereas the release of dehydroepiandrosterone and testosterone was greatly enhanced.
Toxicology in vitro : an international journal published in association with BIBRA  •  1996  |  View Paper
In conclusion, trilostane treatment was effective in decreasing plasma progesterone concentration in bitches during the luteal phase, but the dose regimen used in this study produced less clear-cut inhibition of ovarian steroidogenesis than have other strategies to decrease plasma progesterone concentration.
Trilostane also caused a significant decrease in plasma progesterone concentration.
Theriogenology  •  2011  |  View Paper
In the FST, a co-treatment with trilostane facilitated DHEAS (5-20 mg/kg) antidepressant activity, but showed only an additive, not facilitative, effect with PREGS (10-40 mg/kg), PROG (10-40 mg/kg) or allopregnanolone (ALLO, 1-8 mg/kg).
Trilostane (25 mg/kg) decreased hippocampus PROG contents and paradoxically increased circulating PROG levels.
Neuropharmacology  •  2012  |  View Paper
Trilostane caused a potent inhibition of the rate of conversion of PREG to PROG.
The Journal of Steroid Biochemistry and Molecular Biology  •  2003  |  View Paper
Trilostane , a competitive inhibitor of the 3beta-HSD caused a potent inhibition of the rate of conversion of PREG to PROG (IC50 = 4.06 +/- 2.58 microm).
Journal of neurochemistry  •  2003  |  View Paper
Show More